BioCryst Pharmaceuticals' ORLADEYO Trial Update Highlights Potential for Valuation Reversal

BioCryst Pharmaceuticals (BCRX) has released positive data from its APeX P pediatric trial, showing sustained reductions in hereditary angioedema attacks and confirming the safety of ORLADEYO in children. The company's one-year total shareholder return is -2.32%, but its share price return is 4.37%. Analysts expect earnings to reach $212.3 million by September 2028, with a fair value of $20.40. The valuation story is aggressive and hinges on rapid growth, rising margins, and a premium future earnings multiple. However, there are risks, including competition from new HAE treatments and pipeline program setbacks.